TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female subjects between the ages of 19 and 64 years, both inclusive~* Diagnosed with influenza A at screening using rapid influenza diagnostic test~* Onset of influenza symptoms and fever is within 48 hours at screening~* At least 2 of symptoms (moderate to severe in intensity)~* ≥38.0'C body temperature at screening~Exclusion Criteria:~* Taking antiviral treatment for influenza or has a history of using these antivirals within 14 days prior to the administration of study drug~* Positive influenza B or A+B infection

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- CT-P27 90 mg/kg (Type: EXPERIMENTAL): CT-P27 will be administrated once in IV infusion.
- CT-P27 45mg/kg (Type: EXPERIMENTAL): CT-P27 will be administrated once in IV infusion.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administrated once in IV infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Local Capillary Blood Lactate in Chronic Critical Ischemia of Lower Limb Before and After Revascularization

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ischemia Chronic critical lower limb revascularization procedure requiring fast.~* Written consent informed patient age greater than or equal to 18~Exclusion Criteria:~* Presence of an inflammatory or infectious (erysipelas) in the ischemic member.~* Patients at risk for diabetic foot ie, as defined by the HAS (preventing diabetic foot, 2007)~  * presence of sensory neuropathy, and / or~ * foot deformities (hallux valgus, hammer toes or claw, prominence of the metatarsal heads), and / or~ * history of foot ulceration, and / or~ * antecedent of one of these factors (ie antécedant diabetic foot).~* Necrosis of the toes.~* Participation in another clinical research protocol.~* Presence of peripheral arterial disease in the bilateral upper limbs.~* Patient in shock whatever the cause.~* Presence of hepatic failure.~* Too impaired general condition (bedridden, dementia, ...)~* Refusal of the patient to participate in the study~* Protected patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lactate group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Substudy of Protocol 2019-002498-80 - NCT04223050: Comparing Mortality for Low Vs High Peripheral Oxygen Saturation in COPD-patients with Acute Exacerbation (O2flow-COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 years or older~* ability to give informed consent~* previously diagnosed COPD (either confirmed diagnosis at prior hospital - contact or from their general practitioner or confirmed diagnosis by the treating physician in the emergency department (verified by use of relevant medication))~* admitted with acute exacerbation (acute and worsened shortness of breath) of COPD~* requiring oxygen treatment~Exclusion Criteria:~* Instability at arrival requiring immediate lifesaving treatment, e.g. intubation or non-invasive ventilation, within the first 30 minutes~* Expected total length of stay in hospital \< 12 hours~* Planned transfer to another hospital within 12 hours~* Unwilling to have repeated arterial blood gas analyses within the first 12 hours~* Patients judged terminal by treating physician in the emergency department~* Non-residents of the particular country~* Expected impossible follow-up~* Fertile women (\<50 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG~* Prior participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High oxygen saturation (Type: ACTIVE_COMPARATOR): Peripheral oxygen saturation level \>94% Intervention: Drug: Oxygen gas
- Low oxygen saturation (Type: ACTIVE_COMPARATOR): Peripheral oxygen saturation level 88-92% Intervention: Drug: Oxygen gas

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Senseye's OBCI Diagnostic Tool for PTSD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male/Female diagnosed with PTSD (only for PTSD group)~2. aged 18- 65 years old~3. able to read/write in English~Exclusion Criteria:~1. presence of intellectual disabilities~2. psychotic or self-injurious behavior~3. seizure disorder~4. major depression~5. traumatic brain injury (TBI)~6. language disorder~7. eye disorders~8. other neurodevelopmental disorders~9. history of lifetime psychosis~10. mania~11. current suicidality~12. diagnosis of a substance use disorder~13. impaired functioning to the degree that requires immediate initiation of psychotropic medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Trauma+ & PTSD (Type: None): Patients diagnosed with significant trauma exposure and PTSD
- Trauma+ & No PTSD (Type: None): Patients diagnosed with significant trauma exposure but no PTSD
- No trauma or PTSD (Type: None): Healthy adults without known major psychiatric disorders

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: LIFEGUARD Study - Continuous Respiratory Monitoring on the General Ward

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-cardiac post-surgical patients at high risk of developing respiratory and cardiovascular events (High or intermediate risk for postoperative pulmonary complications).~* Adult age (≥18 year old).~* Patient is able and willing to give informed consent.~Exclusion Criteria:~* Expected ward length of stay ≤24 hours.~* Post-surgical patients with American Society of Anesthesiologists physical status (ASA PS) V or higher.~* Ventilated or intubated patients.~* Patient is unwilling or unable to comply fully with study procedures due to any disease condition which can raise doubt about compliance~* Patient is a member of a vulnerable population regardless of authorized representative support.~* Patient is participating in another potentially confounding drug or device clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Capnostream 20 (Type: OTHER): Continuous monitoring of CO2
- PM1000N-RR (Type: OTHER): Continuous monitoring of SpO2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient successfully completed the Phase 1b/2a study with WVE-004, WVE-004-001.~Exclusion Criteria:~* Patient has a clinically significant medical finding on the physical examination other than C9orf72-associated ALS or FTD that, in the judgment of the Investigator or Sponsor, will make the patient unsuitable for participation in and/or completion of the trial procedures.~* Patient received any other investigational drug, biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Patient received an investigational oligonucleotide within the past 6 months or 5 half-lives of the drug, whichever is longer.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental: WVE-004 (Dose A) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Regional Cerebral Oxygen Saturation Under General Anesthesia A Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with male-to-female ratio approaching 1:1~* age ≥ 18 years~* scheduled duration of surgery longer than or equal to 60 minutes~* patients undergoing one of the following procedures:~  1. orthopedic surgery of the shoulder in beach chair position~ 2. gynecological, urological or general surgery in Trendelenburg's position~ 3. cardiac surgery~Exclusion Criteria:~* Moribund patients~* Persons without the capacity to consent~* Unability of German language use~* Inability of communication due to severe hearing and severe vision impairments~* Accommodation in an institution due to an official or judicial order~* Co-worker of the Charité~* Participation in another interventional study within 30 days before participation in this study~* Alcohol- use disorders according to the Alcohol Use Disorders Identification Test (AUDIT)~* Preoperative Dementia (Minimal Mental State Examination \< 24)~* Stroke, traumatic brain injury within the last 12 months or patients with residual neurological deficits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Orthopedic surgery of the shoulder (Type: None): Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation during change from supine position to beach chair position.
- Gynecological, urological or general surgery (Type: None): Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation during change from supine position to Trendelenburg position.
- Cardiac surgery (Type: None): Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation in patients undergoing cardiac surgery with cardiopulmonary bypass (heart-lung machine).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed extensive-stage disease small cell lung cancer (ED SCLC) at initial diagnosis with ongoing clinical benefit (stable disease \[SD\], partial response \[PR\], or complete response \[CR\]) following completion of 4 cycles of first-line platinum-based therapy~* Participant is eligible to be randomized at least 3 but no more than 9 weeks from Day 1 of the fourth cycle of first-line platinum-based chemotherapy.~* Participants with a history of central nervous system (CNS) metastases prior to the initiation of first-line platinum-based chemotherapy must have received definitive local treatment and have documentation of stable or improved CNS disease status~* Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1~* Participants must have adequate bone marrow, renal and hepatic function~* Availability of archived or representative tumor material for assessment of DLL3 expression~Exclusion Criteria:~* Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint inhibitors, other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, T-cell or other cell-based or biologic therapies, or any other anti-cancer therapy than that described in inclusion criteria for SCLC.~* Any disease-directed radiotherapy (except prophylactic cranial irradiation, palliative radiotherapy to a radiographically documented non-progressing lesion for symptom control, or pre-planned radiotherapy for CNS metastases present prior to start of first-line therapy and non-progressing) after last dose of first-line chemotherapy.~* Prior exposure to a pyrrolobenzodiazepine (PBD-based) or indolinobenzodiazepine-based drug, prior participation in a rovalpituzumab tesirine clinical trial, or known hypersensitivity or other contraindications to rovalpituzumab tesirine or excipient contained in the drug formulation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rovalpituzumab tesirine/dexamethasone (Type: EXPERIMENTAL): Rovalpituzumab tesirine/dexamethasone every 6 weeks (q6 wk); omitting every third cycle
- Placebo (Type: EXPERIMENTAL): Placebo q6 wk; omitting every third cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient must be receiving medical care in an intensive care unit (ICU) (e.g., medical ICU, surgical ICU, cardiothoracic ICU, Trauma ICU, Mixed ICU, other).~2. Adult patients with AKI or other serious conditions who require treatment with CRRT.~3. Patients are expected to remain in the ICU and on CRRT for at least 72 hours after randomization.~4. Patients already receiving standard-of-care CRRT must be randomized within 24 hours of initiation of their standard-of-care CRRT.~Exclusion Criteria:~1. Patients requiring systemic anticoagulation with antithrombotic agents for reasons other than CRRT. The exception is patients receiving subcutaneous heparin for deep vein thrombosis prophylaxis according to institutional practice or patients on aspirin may be enrolled.~2. Patients in whom citrate anticoagulation is contraindicated such as patients with a known allergy to citrate or who have experienced adverse events associated with citrate products including patients with a prior history of citrate toxicity or patients with uncorrected severe hypocalcemia (whether in the context of current citrate administration or due to the underlying disease state).~3. Patients who are not candidates for CRRT.~4. Patients who are receiving extracorporeal membrane oxygenation (ECMO) therapy.~5. Patients with severe coagulopathy \[i.e., platelets \< 30,000/mm3, international normalized ratio (INR) \> 2, partial thromboplastin time (PTT) \> 50 seconds\] including severe thrombocytopenia (platelets \< 30,000/mm3), HIT (heparin induced thrombocytopenia), ITP (idiopathic thrombocytopenia purpura), and TTP (thrombotic thrombocytopenia purpura) should not be enrolled in the trial.~6. Patients with fulminant acute liver failure or acute on chronic liver failure as documented by a Child-Pugh Liver Failure Score \> 10.~7. Patients with refractory shock associated persistent, worsening with lactic acidosis (lactate \> 4 mmol/L). However, patients with improving subsequent serum lactate levels may be enrolled.~8. Patients unlikely to survive at least 72 hours.~9. Female patients who are pregnant, lactating, or planning to become pregnant during the study period.~10. Patients who are currently participating in another interventional clinical study.~11. Patients with a medical condition that may interfere with the study objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prismocitrate 18 (Type: EXPERIMENTAL): None
- No Regional Anticoagulation of CRRT Circuit (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Different Doses of the Vitamin B12 on Recurrent Aphthous Stomatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 and older~* Suffer from RAS For at least one year, with aphthous frequency at least once a month.~Exclusion Criteria:~* known sensitivity to vitamin B12~* Don't speak Hebrew, Russian or English.~* Systemic Diseases, known in developing mouth aphthous (Behcet disease, Lupus Erythematosus, rheumatoid arthritis and AIDS disease)~* Patients who have received last year any form of vitamin B12 .~* Patients who receive a different treatment to RAS(not for pain)~* Pregnant or breastfeeding women~* patient suffering from Leber's optic atrophy~* Patients who suffer from Psychosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- group 1- 1000 mcg (Type: EXPERIMENTAL): Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months
- Group 2- 100 mcg (Type: EXPERIMENTAL): Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months
- group 3- 2000 mcg (Type: EXPERIMENTAL): Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected males or non-pregnant, non-breast-feeding females who are \>= 18 years of age;~* CD4+ T-lymphocyte count less than 250 per mm3;~* Successful response to HAART (defined as an HIV RNA viral load of \<50 copies per mL) for a minimum of one year preceding study enrollment.~Exclusion Criteria:~* Opportunistic infection within the 6 months prior to study enrollment~* Active tuberculosis or other mycobacterial infection~* Uncontrolled high blood pressure or congestive heart failure class III or IV~* Systemic glucocorticoid or immunomodulator therapy within 30 days of study entry~* Prior history of Kaposi's sarcoma~* Prior history of lymphoma~* Active substance abuse within the last 30 days~* Uncontrolled psychiatric disorders, including depression~* Abnormal or inadequate liver or renal function~* Inadequate bone marrow function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Dose Cohort 1: 50 mcg/kg/day of TXA127
- 2 (Type: EXPERIMENTAL): Drug Cohort 2: 100 mcg/kg/day TXA127
- 3 (Type: EXPERIMENTAL): Drug Cohort 3: 200 mcg/kg/day TXA127
- 4 (Type: EXPERIMENTAL): Drug Cohort 4: 300 mcg/kg/day TXA127
- 5 (Type: EXPERIMENTAL): Extended dosing cohort at 300mcg/kg TXA127 for 2 x 28-day treatment cycles, with an extended follow-up period to week 34.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Mentoring on Endotracheal Tube Exchange Using a New Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* physician airway management experts~* training in the skill of fiber-optic endoscopic intubation~Exclusion Criteria:~* non-physicians~* physicians without airway management expertise~* physicians without skill in fiber-optic endoscopic intubation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Control group will study the learning material independently. 'Self-study'.
- Mentored (Type: EXPERIMENTAL): Mentored group will study the learning materials and then receive expert mentoring

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy